| TGF-beta-activated cancer-associated fibroblasts limit cetuximab efficacy in preclinical models of head and neck cancer KM Yegodayev, O Novoplansky, A Golden, M Prasad, L Levin, ... Cancers 12 (2), 339, 2020 | 43 | 2020 |
| TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ... Cancer discovery 11 (1), 126-141, 2021 | 40 | 2021 |
| Ubiquitin accumulation on disease associated protein aggregates is correlated with nuclear ubiquitin depletion, histone de-ubiquitination and impaired DNA damage response A Ben Yehuda, M Risheq, O Novoplansky, K Bersuker, RR Kopito, ... PLoS One 12 (1), e0169054, 2017 | 39 | 2017 |
| Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs DR Jayaram, S Frost, C Argov, VB Liju, NP Anto, A Muraleedharan, ... Proceedings of the National Academy of Sciences 118 (40), e2018899118, 2021 | 37 | 2021 |
| MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer O Novoplansky, M Fury, M Prasad, K Yegodayev, J Zorea, L Cohen, ... International journal of cancer 145 (3), 748-762, 2019 | 27 | 2019 |
| EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation EN Alsahafi, S Thavaraj, N Sarvestani, O Novoplansky, M Elkabets, ... Cancer Letters 498, 80-97, 2021 | 26 | 2021 |
| MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer M Prasad, J Zorea, S Jagadeeshan, AB Shnerb, S Mathukkada, ... Journal for ImmunoTherapy of Cancer 10 (3), 2022 | 25 | 2022 |
| Worldwide prevalence and clinical characteristics of RAS mutations in head and neck cancer: a systematic review and meta-analysis O Novoplansky, S Jagadeeshan, O Regev, I Menashe, M Elkabets Frontiers in Oncology 12, 838911, 2022 | 9 | 2022 |
| The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment Y Greenshpan, O Sharabi, KM Yegodayev, O Novoplansky, M Elkabets, ... International Journal of Molecular Sciences 23 (13), 7431, 2022 | 5 | 2022 |
| Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer O Novoplansky, AB Shnerb, D Marripati, S Jagadeeshan, R Abu Shareb, ... Molecular oncology 17 (12), 2618-2636, 2023 | 4 | 2023 |
| Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy N Tzuri, KM Yegodayev, O Novoplansky, M Elkabets, A Aharoni, N Papo Scientific Reports 13 (1), 11923, 2023 | 3 | 2023 |
| Abstract P42: Beyond the Canonical: uORF-encoded Micro Peptides as Novel Kinase Inhibitors in Cancer Therapy DR Jayaram, S Frost, C Argov, VB Liju, NP Anto, A Muraleedharan, ... Cancer Research 84 (8_Supplement), P42-P42, 2024 | | 2024 |
| New insights into RAS in head and neck cancer S Jagadeeshan, OZ Novoplansky, O Cohen, I Kurth, J Hess, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 188963, 2023 | | 2023 |
